FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																		
Name and Address of Reporting Person * Latkin Jed				2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X Officer (give title below) Other (specify below) CEO, COO & CFO								
(Last) (First) (Middle) 4995 BRADENTON AVE., SUITE 240				3. Date of Earliest Transaction (Month/Day/Year) 06/05/2019									Cr	EO, COO &	CFO					
(Street) DUBLIN, OH 43017				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City) (State) (Zip)				p)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1.Title of Security (Instr. 3)		Date	Date (Month/Day/Year) a		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		ion 4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		of (E	Benefici Reported (Instr. 3		unt of Securities ally Owned Following d Transaction(s) and 4)		Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common	Stock		06/05/20	019				P	ie	V	1,000	(D)	Pri \$ 1.25		12,950			(Instr. d	+)	
			T	able II - D	Derivat	ive Sec	uriti	es Ac		con the	tained i form dis	n this i splays	form a cu	are i	not requ tly valid		ormation spond unle trol numbe	SS	SEC 14	74 (9-02)
	1_	1			<u> </u>				s, opt		s, conver					l				1
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transacti Date (Month/Day	Executive (Year) Executive (Year)	r) any	4. Transaction Code Year) (Instr. 8)		ion	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and	6. Date Exercisable and Expiration Date (Month/Day/Year)		: I	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ow For Der Sec Dir or I (s) (I)	nership m of ivative urity: ect (D) ndirect etr. 4)	(Instr. 4)
						Code	V	(A)	(D)	Dat Exe	-	Expirat Date	tion	Title	Amount or Number of Shares					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Latkin Jed 4995 BRADENTON AVE., SUITE 240 DUBLIN, OH 43017	X		CEO, COO & CFO				

Signatures

/s/ Jed A. Latkin	06/07/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.